GIST as the model of paradigm shift towards targeted therapy of solid tumors: update and perspective on trial design.
Verweij
Jaap
J
Erasmus University Medical Center, Daniel den Hoed Cancer Center, Department of Medical Oncology, Rotterdam, The Netherlands. j.verweij@erasmusmc.nl
Seynaeve
Caroline
C
Sleijfer
Stefan
S
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D018572:Disease-Free Survival; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D005838:Genotype; D006801:Humans; D008495:Medical Oncology / Q000379:methods; D008954:Models, Biological; D015999:Multivariate Analysis; D009154:Mutation; D009362:Neoplasm Metastasis; D019009:Proto-Oncogene Proteins c-kit / Q000378:metabolism*; D012107:Research Design; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D019009:Proto-Oncogene Proteins c-kit